News – Alligator Bioscience

2025-12-09

Alligator Bioscience comments on Henlius receiving regulatory approval in China to initiate Phase 2/3 trials of HLX22 in HER2-positive breast cancer

Lund, Sweden – 9 Dec 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henliu ...

2025-12-03

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-12-03

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2026: Deadline for Alligato ...

2025-12-01

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-12-01

Lund, Sweden, 1 December 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the publication of a peer-reviewed arti ...

2025-11-28

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-11-25

Regulatory

Today, on 25 November 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follo ...

2025-11-24

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-11-05

Lund, Sweden – 5 November 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developi ...